These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9323326)

  • 1. Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B.
    Kawanishi C; Hanihara T; Maruyama Y; Matsumura T; Onishi H; Inoue K; Sugiyama N; Suzuki K; Yamada Y; Kosaka K
    Psychiatr Genet; 1997; 7(3):127-9. PubMed ID: 9323326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity.
    Kawanishi C; Furuno T; Onishi H; Sugiyama N; Suzuki K; Matsumura T; Ishigami T; Kosaka K
    Psychiatr Genet; 2000 Sep; 10(3):145-7. PubMed ID: 11204351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome.
    Kawanishi C; Shimoda Y; Fujimaki J; Onishi H; Suzuki K; Hanihara T; Sugiyama N; Kosaka K
    J Neurol Sci; 1998 Sep; 160(1):102-4. PubMed ID: 9804127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6 HhaI genotype and the neuroleptic malignant syndrome.
    Iwahashi K; Yoshihara E; Nakamura K; Ameno K; Watanabe M; Tsuneoka Y; Ichikawa Y; Igarashi K
    Neuropsychobiology; 1999; 39(1):33-7. PubMed ID: 9892857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2D6 Hhal genotype and the neuroleptic malignant syndrome (NMS).
    Iwahashi K; Nakamura K; Suwaki H; Tsuneoka Y; Ichikawa Y
    Clin Chim Acta; 1997 Sep; 265(1):143-4. PubMed ID: 9352138
    [No Abstract]   [Full Text] [Related]  

  • 6. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
    Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
    Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report.
    Kato D; Kawanishi C; Kishida I; Furuno T; Matsumura T; Hasegawa H; Suzuki K; Hirayasu Y
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):504-7. PubMed ID: 16048458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia.
    Dawson E; Powell JF; Nöthen MM; Crocq MA; Lanczik M; Körner J; Rietschel M; van Os J; Wright P; Gill M
    Psychiatr Genet; 1994; 4(4):215-8. PubMed ID: 7712118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia.
    Jönsson EG; Dahl ML; Roh HK; Jerling M; Sedvall GC
    Psychiatr Genet; 1998; 8(1):25-8. PubMed ID: 9564684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
    Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
    Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
    Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Debrisoquine 4-hydroxylase (CYP2D6) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan.
    Chen CH; Hung CC; Wei FC; Koong FJ
    Psychiatr Genet; 2001 Sep; 11(3):153-5. PubMed ID: 11702057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation.
    Ochi S; Kawasoe K; Abe M; Fukuhara R; Sonobe K; Kawabe K; Ueno S
    Gen Hosp Psychiatry; 2011; 33(6):640.e1-2. PubMed ID: 21749835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients.
    Llerena A; Dorado P; Peñas-Lledó EM; Cáceres MC; De la Rubia A
    Pharmacogenomics J; 2007 Dec; 7(6):408-10. PubMed ID: 17325735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroleptic malignant syndrome in an adolescent with CYP2D6 deficiency.
    Butwicka A; Krystyna S; Retka W; Wolańczyk T
    Eur J Pediatr; 2014 Dec; 173(12):1639-42. PubMed ID: 24253372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P-450 2D6 gene polymorphism is not associated with neuroleptic malignant syndrome.
    Ueno S; Otani K; Kaneko S; Koshiro K; Kondoh K; Kotani Y; Sano A
    Biol Psychiatry; 1996 Jul; 40(1):72-4. PubMed ID: 8780858
    [No Abstract]   [Full Text] [Related]  

  • 17. CYP2D6 polymorphism in systemic lupus erythematosus patients.
    Kortunay S; Bozkurt A; Bathum L; Basci NE; Calgüneri M; Brøsen K; Kayaalp SO
    Eur J Clin Pharmacol; 1999 Mar; 55(1):21-5. PubMed ID: 10206080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients.
    Inada T; Senoo H; Iijima Y; Yamauchi T; Yagi G
    Psychiatr Genet; 2003 Sep; 13(3):163-8. PubMed ID: 12960748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
    Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome.
    Kato D; Kawanishi C; Kishida I; Furuno T; Suzuki K; Onishi H; Hirayasu Y
    Eur J Clin Pharmacol; 2007 Nov; 63(11):991-6. PubMed ID: 17701031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.